Logo image of TSHA

TAYSHA GENE THERAPIES INC (TSHA) Stock Fundamental Analysis

NASDAQ:TSHA - Nasdaq - US8776191061 - Common Stock - Currency: USD

1.61  -0.03 (-1.83%)

After market: 1.659 +0.05 (+3.04%)

Fundamental Rating

2

Taking everything into account, TSHA scores 2 out of 10 in our fundamental rating. TSHA was compared to 572 industry peers in the Biotechnology industry. TSHA may be in some trouble as it scores bad on both profitability and health. TSHA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TSHA had positive earnings in the past year.
TSHA had a negative operating cash flow in the past year.
TSHA had negative earnings in each of the past 5 years.
In the past 5 years TSHA always reported negative operating cash flow.
TSHA Yearly Net Income VS EBIT VS OCF VS FCFTSHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of -12.64%, TSHA belongs to the best of the industry, outperforming 86.15% of the companies in the same industry.
With an excellent Return On Equity value of -25.65%, TSHA belongs to the best of the industry, outperforming 81.88% of the companies in the same industry.
Industry RankSector Rank
ROA -12.64%
ROE -25.65%
ROIC N/A
ROA(3y)-92.53%
ROA(5y)N/A
ROE(3y)-6259.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TSHA Yearly ROA, ROE, ROICTSHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -5K -10K -15K

1.3 Margins

TSHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSHA Yearly Profit, Operating, Gross MarginsTSHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TSHA has more shares outstanding
The debt/assets ratio for TSHA has been reduced compared to a year ago.
TSHA Yearly Shares OutstandingTSHA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
TSHA Yearly Total Debt VS Total AssetsTSHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.94, we must say that TSHA is in the distress zone and has some risk of bankruptcy.
TSHA has a Altman-Z score (-2.94) which is comparable to the rest of the industry.
TSHA has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
TSHA has a worse Debt to Equity ratio (0.48) than 75.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -2.94
ROIC/WACCN/A
WACC9.91%
TSHA Yearly LT Debt VS Equity VS FCFTSHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 5.51 indicates that TSHA has no problem at all paying its short term obligations.
With a Current ratio value of 5.51, TSHA perfoms like the industry average, outperforming 58.26% of the companies in the same industry.
A Quick Ratio of 5.51 indicates that TSHA has no problem at all paying its short term obligations.
The Quick ratio of TSHA (5.51) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.51
Quick Ratio 5.51
TSHA Yearly Current Assets VS Current LiabilitesTSHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 155.75% over the past year.
TSHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -30.95%.
EPS 1Y (TTM)155.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
Revenue 1Y (TTM)-30.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.33%

3.2 Future

The Earnings Per Share is expected to decrease by -34.21% on average over the next years. This is quite bad
TSHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 60.38% yearly.
EPS Next Y-396.23%
EPS Next 2Y-123.3%
EPS Next 3Y-73.44%
EPS Next 5Y-34.21%
Revenue Next Year-42.96%
Revenue Next 2Y-41.37%
Revenue Next 3Y-35.97%
Revenue Next 5Y60.38%

3.3 Evolution

TSHA Yearly Revenue VS EstimatesTSHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TSHA Yearly EPS VS EstimatesTSHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TSHA is valuated cheaply with a Price/Earnings ratio of 2.56.
Based on the Price/Earnings ratio, TSHA is valued cheaply inside the industry as 99.29% of the companies are valued more expensively.
TSHA is valuated cheaply when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for TSHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 2.56
Fwd PE N/A
TSHA Price Earnings VS Forward Price EarningsTSHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSHA Per share dataTSHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

TSHA's earnings are expected to decrease with -73.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-123.3%
EPS Next 3Y-73.44%

More info and screens

0

5. Dividend

5.1 Amount

TSHA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TAYSHA GENE THERAPIES INC

NASDAQ:TSHA (2/21/2025, 8:00:01 PM)

After market: 1.659 +0.05 (+3.04%)

1.61

-0.03 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)02-26 2025-02-26/bmo
Inst Owners83.26%
Inst Owner Change-96.25%
Ins Owners1.56%
Ins Owner Change6.89%
Market Cap329.95M
Analysts83.53
Price Target6.68 (314.91%)
Short Float %14.39%
Short Ratio9.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.27%
Min EPS beat(2)-5.87%
Max EPS beat(2)46.41%
EPS beat(4)3
Avg EPS beat(4)242.72%
Min EPS beat(4)-5.87%
Max EPS beat(4)919.96%
EPS beat(8)5
Avg EPS beat(8)124.82%
EPS beat(12)7
Avg EPS beat(12)84.69%
EPS beat(16)7
Avg EPS beat(16)46.43%
Revenue beat(2)1
Avg Revenue beat(2)-26.35%
Min Revenue beat(2)-59.07%
Max Revenue beat(2)6.37%
Revenue beat(4)3
Avg Revenue beat(4)2.8%
Min Revenue beat(4)-59.07%
Max Revenue beat(4)33.33%
Revenue beat(8)6
Avg Revenue beat(8)56.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.64%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.91%
EPS NY rev (1m)0%
EPS NY rev (3m)2.09%
Revenue NQ rev (1m)11.08%
Revenue NQ rev (3m)-18.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.27%
Valuation
Industry RankSector Rank
PE 2.56
Fwd PE N/A
P/S 33.28
P/FCF N/A
P/OCF N/A
P/B 3.72
P/tB 3.72
EV/EBITDA N/A
EPS(TTM)0.63
EY39.13%
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.05
BVpS0.43
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.64%
ROE -25.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-92.53%
ROA(5y)N/A
ROE(3y)-6259.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.34%
Cap/Sales 3.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.51
Quick Ratio 5.51
Altman-Z -2.94
F-Score3
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)1722.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)155.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
EPS Next Y-396.23%
EPS Next 2Y-123.3%
EPS Next 3Y-73.44%
EPS Next 5Y-34.21%
Revenue 1Y (TTM)-30.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.33%
Revenue Next Year-42.96%
Revenue Next 2Y-41.37%
Revenue Next 3Y-35.97%
Revenue Next 5Y60.38%
EBIT growth 1Y-11.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.25%
EBIT Next 3Y33.92%
EBIT Next 5YN/A
FCF growth 1Y53.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.87%
OCF growth 3YN/A
OCF growth 5YN/A